Advertisement

Epigenetic mechanisms in Parkinson's disease

  • Author Footnotes
    1 Ya Feng and Joseph Jankovic contributed equally.
    Ya Feng
    Footnotes
    1 Ya Feng and Joseph Jankovic contributed equally.
    Affiliations
    Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China
    Search for articles by this author
  • Author Footnotes
    1 Ya Feng and Joseph Jankovic contributed equally.
    Joseph Jankovic
    Footnotes
    1 Ya Feng and Joseph Jankovic contributed equally.
    Affiliations
    Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Search for articles by this author
  • Yun-Cheng Wu
    Correspondence
    Corresponding author. Tel.: +86 21 37797112; fax: +86 21 63240825.
    Affiliations
    Department of Neurology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China
    Search for articles by this author
  • Author Footnotes
    1 Ya Feng and Joseph Jankovic contributed equally.
Published:December 18, 2014DOI:https://doi.org/10.1016/j.jns.2014.12.017

      Highlights

      • The alternation of DNA methylation in PD-related genes and methylation associated factors changes.
      • Histone modifications occurred in PD.
      • Changes of non-coding RNAs found in PD.
      • Epigenetic-based diagnosis and therapeutic strategies for PD patients.

      Abstract

      Parkinson's disease (PD) is the second most common age-related neurodegenerative disease, but its pathogenesis is not fully understood. The selective neuronal cell death in PD has been considered to result from a complex interaction between genetic and environmental factors, but the nature of the relationship between the two chief modifiers remains to be elucidated. There is a growing body of evidence supporting the role of epigenetics in the development and progression of many neurodegenerative diseases including PD. Epigenetic modification refers to changes in gene expression or function without changes in DNA sequence, which mainly includes DNA methylation, post-modifications of histone, and non-coding RNAs. In this review, we will focus on the abnormal epigenetic modifications involved in the pathogenesis of PD and their implications for the development of future diagnostic and therapeutic strategies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ozansoy M.
        • Basak A.N.
        The central theme of Parkinson's disease: alpha-synuclein.
        Mol Neurobiol. 2013; 47: 460-465
        • Wu Y.
        • Le W.
        • Jankovic J.
        Preclinical biomarkers of Parkinson disease.
        Arch Neurol. 2011; 68: 22-30
        • Kalia L.V.
        • Kalia S.K.
        • McLean P.J.
        • Lozano A.M.
        • Lang A.E.
        alpha-Synuclein oligomers and clinical implications for Parkinson disease.
        Ann Neurol. 2013; 73: 155-169
        • Jiang T.F.
        • Chen S.D.
        Dysfunction of two lysosome degradation pathways of alpha-synuclein in Parkinson's disease: potential therapeutic targets?.
        Neurosci Bull. 2012; 28: 649-657
        • Oliveras-Salva M.
        • Van der Perren A.
        • Casadei N.
        • Stroobants S.
        • Nuber S.
        • D'Hooge R.
        • et al.
        rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
        Mol Neurodegener. 2013; 8: 44
        • Desplats P.
        • Patel P.
        • Kosberg K.
        • Mante M.
        • Patrick C.
        • Rockenstein E.
        • et al.
        Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease.
        Mol Neurodegener. 2012; 7: 49
        • Marques S.C.
        • Oliveira C.R.
        • Pereira C.M.
        • Outeiro T.F.
        Epigenetics in neurodegeneration: a new layer of complexity.
        Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35: 348-355
        • Portela A.
        • Esteller M.
        Epigenetic modifications and human disease.
        Nat Biotechnol. 2010; 28: 1057-1068
        • Ammal Kaidery N.
        • Tarannum S.
        • Thomas B.
        Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities.
        Neurotherapeutics. 2013; 10: 698-708
        • Day J.J.
        • Sweatt J.D.
        DNA methylation and memory formation.
        Nat Neurosci. 2010; 13: 1319-1323
        • Guo J.U.
        • Ma D.K.
        • Mo H.
        • Ball M.P.
        • Jang M.H.
        • Bonaguidi M.A.
        • et al.
        Neuronal activity modifies the DNA methylation landscape in the adult brain.
        Nat Neurosci. 2011; 14: 1345-1351
        • Qureshi I.A.
        • Mehler M.F.
        Advances in epigenetics and epigenomics for neurodegenerative diseases.
        Curr Neurol Neurosci Rep. 2011; 11: 464-473
        • Klein C.J.
        • Benarroch E.E.
        Epigenetic regulation: basic concepts and relevance to neurologic disease.
        Neurology. 2014; 82: 1833-1840
        • Long X.R.
        • He Y.
        • Huang C.
        • Li J.
        MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis.
        Int J Oncol. 2014; 44: 1915-1922
        • Wienholz B.L.
        • Kareta M.S.
        • Moarefi A.H.
        • Gordon C.A.
        • Ginno P.A.
        • Chedin F.
        DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo.
        PLoS Genet. 2010; 6: e1001106
        • Cao J.X.
        • Zhang H.P.
        • Du L.X.
        Influence of environmental factors on DNA methylation.
        Yi Chuan. 2013; 35: 839-846
        • Laffita-Mesa J.M.
        • Bauer P.
        Epigenetic heredity (deoxyribonucleic acid methylation): clinical context in neurodegenerative disorders and ATXN2 gene.
        Med Clin (Barc). 2014; 143: 360-365
        • Dhobale M.V.
        • Pisal H.R.
        • Mehendale S.S.
        • Joshi S.R.
        Differential expression of human placental neurotrophic factors in preterm and term deliveries.
        Int J Dev Neurosci. 2013; 31: 719-723
        • Coppede F.
        One-carbon metabolism and Alzheimer's disease: focus on epigenetics.
        Curr Genomics. 2010; 11: 246-260
        • Duan W.
        • Ladenheim B.
        • Cutler R.G.
        • Kruman I.I.
        • Cadet J.L.
        • Mattson M.P.
        Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.
        J Neurochem. 2002; 80: 101-110
        • Ceravolo R.
        • Cossu G.
        • Bandettini di Poggio M.
        • Santoro L.
        • Barone P.
        • Zibetti M.
        • et al.
        Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.
        Mov Disord. 2013; 28: 1391-1397
        • Szadejko K.
        • Szabat K.
        • Ludwichowska A.
        • Sławek J.
        Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders.
        Przegl Lek. 2012; 70: 443-447
        • Sapkota S.
        • Gee M.
        • Sabino J.
        • Emery D.
        • Camicioli R.
        Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease.
        Mov Disord. 2014; 29: 368-374
        • Jara-Prado A.
        • Ortega-Vazquez A.
        • Martinez-Ruano L.
        • Rios C.
        • Santamaria A.
        Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition.
        Neurotox Res. 2003; 5: 237-243
        • McCully K.S.
        Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation.
        Ann Clin Lab Sci. 2009; 39: 219-232
        • Kruman I.I.
        • Culmsee C.
        • Chan S.L.
        • Kruman Y.
        • Guo Z.
        • Penix L.
        • et al.
        Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity.
        J Neurosci. 2000; 20: 6920-6926
        • Marsden C.D.
        Parkinson's disease.
        J Neurol Neurosurg Psychiatry. 1994; 57: 672-681
        • Searles Nielsen S.
        • Checkoway H.
        • Butler R.A.
        • Nelson H.H.
        • Farin F.M.
        • Longstreth Jr., W.T.
        • et al.
        LINE-1 DNA methylation, smoking and risk of Parkinson's disease.
        J Park Dis. 2012; 2: 303-308
        • van der Mark M.
        • Nijssen P.C.
        • Vlaanderen J.
        • Huss A.
        • Mulleners W.M.
        • Sas A.M.
        • et al.
        A case–control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking.
        PLoS One. 2014; 9: e95297
        • Singleton A.
        • Farrer M.
        • Johnson J.
        • Singleton A.
        • Hague S.
        • Kachergus J.
        • et al.
        α-Synuclein locus triplication causes Parkinson's disease.
        Science. 2003; 302: 841
        • Edwards T.L.
        • Scott W.K.
        • Almonte C.
        • Burt A.
        • Powell E.H.
        • Beecham G.W.
        • et al.
        Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease.
        Ann Hum Genet. 2010; 74: 97-109
        • Ai S.X.
        • Xu Q.
        • Hu Y.C.
        • Song C.Y.
        • Guo J.F.
        • Shen L.
        • et al.
        Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease.
        J Neurol Sci. 2014; 337: 123-128
        • Matsumoto L.
        • Takuma H.
        • Tamaoka A.
        • Kurisaki H.
        • Date H.
        • Tsuji S.
        • et al.
        CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease.
        PLoS One. 2010; 5: e15522
        • Tan Y.Y.
        • Wu L.
        • Zhao Z.B.
        • Wang Y.
        • Xiao Q.
        • Liu J.
        • et al.
        Methylation of alpha-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
        Parkinsonism Relat Disord. 2014; 20: 308-313
        • Song Y.
        • Ding H.
        • Yang J.
        • Lin Q.
        • Xue J.
        • Zhang Y.
        • et al.
        Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson's disease patients.
        Neurosci Lett. 2014; 569: 85-88
        • Desplats P.
        • Spencer B.
        • Coffee E.
        • Patel P.
        • Michael S.
        • Patrick C.
        • et al.
        Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases.
        J Biol Chem. 2011; 286: 9031-9037
        • Pankratz N.
        • Wilk J.B.
        • Latourelle J.C.
        • DeStefano A.L.
        • Halter C.
        • Pugh E.W.
        • et al.
        Genomewide association study for susceptibility genes contributing to familial Parkinson disease.
        Hum Genet. 2009; 124: 593-605
        • Coupland K.G.
        • Mellick G.D.
        • Silburn P.A.
        • Mather K.
        • Armstrong N.J.
        • Sachdev P.S.
        • et al.
        DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro.
        Mov Disord. 2014; 29: 1606-1614
        • Riedl A.G.
        • Watts P.M.
        • Jenner P.
        • Marsden C.D.
        P450 enzymes and Parkinson's disease: the story so far.
        Mov Disord. 1998; 13: 212-220
        • Kaut O.
        • Schmitt I.
        • Wullner U.
        Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1.
        Neurogenetics. 2012; 13: 87-91
        • Pieper H.C.
        • Evert B.O.
        • Kaut O.
        • Riederer P.F.
        • Waha A.
        • Wullner U.
        Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability.
        Neurobiol Dis. 2008; 32: 521-527
        • Kouzarides T.
        Chromatin modifications and their function.
        Cell. 2007; 128: 693-705
        • Wang Y.
        • Miao X.
        • Liu Y.
        • Li F.
        • Liu Q.
        • Sun J.
        • et al.
        Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases.
        Oxid Med Cell Longev. 2014; 2014: 641979
        • Grayson D.R.
        • Kundakovic M.
        • Sharma R.P.
        Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?.
        Mol Pharmacol. 2010; 77: 126-135
        • Outeiro T.F.
        • Kontopoulos E.
        • Altmann S.M.
        • Kufareva I.
        • Strathearn K.E.
        • Amore A.M.
        • et al.
        Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease.
        Science. 2007; 317: 516-519
        • Harrison I.F.
        • Dexter D.T.
        Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?.
        Pharmacol Ther. 2013; 140: 34-52
        • Siddiqui A.
        • Chinta S.J.
        • Mallajosyula J.K.
        • Rajagopolan S.
        • Hanson I.
        • Rane A.
        • et al.
        Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease.
        Free Radic Biol Med. 2012; 53: 993-1003
        • Kanthasamy A.
        • Jin H.
        • Anantharam V.
        • Sondarva G.
        • Rangasamy V.
        • Rana A.
        • et al.
        Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration.
        Neurotoxicology. 2012; 33: 833-837
        • Song C.
        • Kanthasamy A.
        • Jin H.
        • Anantharam V.
        • Kanthasamy A.
        Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration.
        Neurotoxicology. 2011; 32: 586-595
        • Song C.
        • Kanthasamy A.
        • Anantharam V.
        • Sun F.
        • Kanthasamy A.G.
        Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration.
        Mol Pharmacol. 2010; 77: 621-632
        • Berthier A.
        • Jimenez-Sainz J.
        • Pulido R.
        PINK1 regulates histone H3 trimethylation and gene expression by interaction with the polycomb protein EED/WAIT1.
        Proc Natl Acad Sci U S A. 2013; 110: 14729-14734
        • Coppede F.
        Genetics and epigenetics of Parkinson's disease.
        ScientificWorldJournal. 2012; 2012: 489830
        • Johnson R.
        • Noble W.
        • Tartaglia G.G.
        • Buckley N.J.
        Neurodegeneration as an RNA disorder.
        Prog Neurobiol. 2012; 99: 293-315
        • Kozina E.A.
        • Khakimova G.R.
        • Khaindrava V.G.
        • Kucheryanu V.G.
        • Vorobyeva N.E.
        • Krasnov A.N.
        • et al.
        Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
        J Neurol Sci. 2014; 340: 198-207
        • Kim J.
        • Inoue K.
        • Ishii J.
        • Vanti W.B.
        • Voronov S.V.
        • Murchison E.
        • et al.
        A MicroRNA feedback circuit in midbrain dopamine neurons.
        Science. 2007; 317: 1220-1224
        • Jankovic J.
        • Chen S.
        • Le W.D.
        The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease.
        Prog Neurobiol. 2005; 77: 128-138
        • Kanagaraj N.
        • Beiping H.
        • Dheen S.T.
        • Tay S.S.
        Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
        Neuroscience. 2014; 272: 167-179
        • Kim W.
        • Lee Y.
        • McKenna N.D.
        • Yi M.
        • Simunovic F.
        • Wang Y.
        • et al.
        miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling.
        Neurobiol Aging. 2014; 35: 1712-1721
        • Junn E.
        • Lee K.W.
        • Jeong B.S.
        • Chan T.W.
        • Im J.Y.
        • Mouradian M.M.
        Repression of alpha-synuclein expression and toxicity by microRNA-7.
        Proc Natl Acad Sci U S A. 2009; 106: 13052-13057
        • Doxakis E.
        Post-transcriptional regulation of α-synuclein expression by mir-7 and mir-153.
        J Biol Chem. 2010; 285: 12726-12734
        • Alvarez-Erviti L.
        • Seow Y.
        • Schapira A.H.
        • Rodriguez-Oroz M.
        • Obeso J.
        • Cooper J.
        Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.
        Cell Death Dis. 2013; 4: e545
        • Saito Y.
        • Saito H.
        MicroRNAs in cancers and neurodegenerative disorders.
        Front Genet. 2012; 3: 194
        • Xiong R.
        • Wang Z.
        • Zhao Z.
        • Li H.
        • Chen W.
        • Zhang B.
        • et al.
        MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration.
        Neurobiol Aging. 2014; 35: 705-714
        • Alvarez-Erviti L.
        • Seow Y.
        • Schapira A.H.
        • Rodriguez-Oroz M.C.
        • Obeso J.A.
        • Cooper J.M.
        Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease.
        Cell Death Dis. 2013; 4: e545
        • Masliah E.
        • Dumaop W.
        • Galasko D.
        • Desplats P.
        Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes.
        Epigenetics. 2013; 8: 1030-1038
        • Margis R.
        • Rieder C.R.
        Identification of blood microRNAs associated to Parkinson's disease.
        J Biotechnol. 2011; 152: 96-101
        • Konsoula Z.
        • Barile F.A.
        Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
        J Pharmacol Toxicol Methods. 2012; 66: 215-220
        • Xu Z.
        • Li H.
        • Jin P.
        Epigenetics-based therapeutics for neurodegenerative disorders.
        Curr Transl Geriatr Exp Gerontol Rep. 2012; 1: 229-236
        • Narayan P.
        • Dragunow M.
        Pharmacology of epigenetics in brain disorders.
        Br J Pharmacol. 2010; 159: 285-303
        • Wang Y.
        • Wang X.
        • Li R.
        • Yang Z.F.
        • Wang Y.Z.
        • Gong X.L.
        • et al.
        A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons.
        CNS Neurosci Ther. 2013; 19: 183-190
        • Kato N.
        • Yamamoto H.
        • Adachi Y.
        • Ohashi H.
        • Taniguchi H.
        • Suzuki H.
        • et al.
        Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids.
        World J Gastroenterol. 2013; 19: 1718-1727
        • Abel T.
        • Zukin R.S.
        Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders.
        Curr Opin Pharmacol. 2008; 8: 57-64
        • Zhu M.
        • Li W.W.
        • Lu C.Z.
        Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+.
        CNS Neurosci Ther. 2014; 20: 308-316
        • Kidd S.K.
        • Schneider J.S.
        Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
        Neuroscience. 2011; 194: 189-194
        • Peng G.S.
        • Li G.
        • Tzeng N.S.
        • Chen P.S.
        • Chuang D.M.
        • Hsu Y.D.
        • et al.
        Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia.
        Brain Res Mol Brain Res. 2005; 134: 162-169
        • Nicholas A.P.
        • Lubin F.D.
        • Hallett P.J.
        • Vattem P.
        • Ravenscroft P.
        • Bezard E.
        • et al.
        Striatal histone modifications in models of levodopa-induced dyskinesia.
        J Neurochem. 2008; 106: 486-494
        • Darmopil S.
        • Martin A.B.
        • De Diego I.R.
        • Ares S.
        • Moratalla R.
        Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation.
        Biol Psychiatry. 2009; 66: 603-613
        • Palm T.
        • Bahnassawy L.
        • Schwamborn J.
        MiRNAs and neural stem cells: a team to treat Parkinson's disease?.
        RNA Biol. 2012; 9: 720-730